• No results found

<p>Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not</p>

N/A
N/A
Protected

Academic year: 2020

Share "<p>Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not</p>"

Copied!
6
0
0

Loading.... (view fulltext now)

Full text

Loading

Figure

Figure 1 (Abbreviations:A) Cmax and (B) Cmin concentration of serum panitumumab versus body weight for patients in clinical trials receiving panitumumab 6 mg/kg Q2W
Table 2 Simulated AUCtau Values for Patients Modeled to Receive Panitumumab Q2W as a Fixed or Body Weight–BasedDose

References

Related documents

2: Radial ductal US, with the nipple in the left-upper corner of the screen illustrates in R: 9:00 a typically malignant breast mass upon the US BI-RADS with demonstration of

In the segmentation, the input image is segmented into individual characters and then, each character is resized into m x n pixels towards the training

HRQoL: Health-related quality of life; IxeQ2W: 80 mg IXE ixekizumab every 2 weeks; IxeQ4W: 80 mg IXE ixekizumab every 4 weeks; MCID: Minimum clinically important differences;

The main objective of the presented method was to provide a precise and automatic determination of the spatial curve of thoracic and lumbar spine based on the 3D shape measurement

%DOI: Percentage of the degree of impairment; 6MWT: 6-Min Walk Test; BMI: Body Mass Index; CBRP: Community-based rehabilitation programmes with maintenance pulmonary

A teacher’s choice of representations has the potential to help us understand how a teacher translates his/her knowledge and beliefs about teaching and learning science

correlation design) study. Samples included 305 nursing students studying at the Shahid Beheshti School of Nursing and Midwifery, Rasht, who were recruited by the

Other reports support our data for a rela- tively high incidence of small, asymptomatic sub- dural hemorrhages not associated with adverse neu- rologic outcome.27#{176} These